Reference number(s)
7610-A

Specialty Guideline Management
Etcamah

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Etcamah	camizestrant

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications[1]

Etcamah, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib), is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.

All other indications are considered experimental/investigational and not medically necessary.

Documentation

Submission of the following information is necessary to initiate the prior authorization review:

- HR and HER2 receptor mutation status
- ESR1 mutation status

© 2026 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

Coverage Criteria

Breast Cancer

Authorization of 12 months may be granted for the subsequent treatment of locally advanced or metastatic breast cancer when all of the following criteria are met:

- The tumor is HR-positive, HER2-negative, and ESR1-positive.
- The requested medication will be used in combination with a CDK4/6 inhibitor (e.g., Verzenio [abemaciclib], Ibrance [palbociclib], Kisqali [ribociclib]).
- The member has previously received an aromatase inhibitor.

Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the coverage criteria section when there is no evidence of disease progression or unacceptable toxicity while on the current regimen.

References

1. Etcamah [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; September 2026.

© 2026 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.